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INTRODUCTION
Hemophagocytic Lymphohistiocytosis (HLH) is a rare,
life-threatening syndrome of overwhelming inflammation
caused by activation and proliferation of T-lymphocytes
and hemophagocytic macrophages.1 This uncontrolled
proliferation of macrophages creates a cytokine storm
with resultant tissue damage. HLH is associated with
clinical and laboratory findings which include fever,
cytopenias, hepatic dysfunction, splenomegaly, and
marked hyperferritinemia. 1-3 There exists limited
epidemiologic data on adult (age ≥ 18 years) cases of
HLH, and its incidence is uncertain.2,4 HLH can be due to
inherited mutations causing immune system
dysregulation or secondary to underlying malignancy,
infection, or rheumatologic condition. Macrophage
activation syndrome (MAS) refers to HLH that occurs
secondary to rheumatologic diseases.5 Approximately 8%
of HLH cases in adults occur secondary to rheumatologic
diseases.4 The overall 30-day mortality for HLH in adult
patients is approximately 44% and can be related to the
underlying trigger with malignancy-associated HLH
patients having a higher mortality.4 A key barrier to HLH
treatment in adults is delay in diagnosis given the lack of
specific laboratory findings to distinguish it from bacterial
sepsis.1,2 The treatment for HLH in adults, beyond early
initiation of steroids, remains unclear given its rarity, with
much of our understanding of HLH derived from the
pediatric literature.5

Figure 1. Erythematous rash involving the back.

Physical exam was significant for conjunctival injection
and icterus, tachycardia, and blanching erythematous
patches involving the chest, upper arms and back
(Figure 1). The patient’s admission labs were notable for
hyperbilirubinemia, transaminitis, thrombocytopenia,
and leukopenia with significant bandemia (Table 1).

Table 1: Labs for Admission to the hospital
Lab

Result

Lab

Result

CASE PRESENTATION

Hemoglobin (g/dL)

13.2 L

AST (IU/L)

480 H

A 26-year-old man presented to an outside Emergency
Department (ED) with 3 days of fevers to 103°F, headache,
and rash on his upper chest and upper extremities. He was
discharged home with ibuprofen, but represented to the
ED when his fevers did not resolve. The patient had a
history notable for Raynaud’s syndrome diagnosed as a
toddler. Five months prior to admission, he was hospitalized
for a pyogenic hepatic abscess for which he underwent
percutaneous drainage and a 6-week course of ciprofloxacin
and metronidazole. His only complaint was vague right
upper abdominal soreness. Vital signs were notable for
heart rate of 115 beats/minute and fever to 102.2°F.

WBC (B/L)

2.8 with 66%
bands L

ALT (IU/L)

591 H

Platelets (B/L)

86 L

Total Bilirubin
(mg/dL)

3.9 H

BUN (mg/dL)

8

Albumin (g/dL)

3.9

0.9

ANA titer

>1:640 H

Ferritin (ng/mL)

6881 H

Anti-RNP/SM
ELISA (U/mL)

>1562 H

LDH (IU/L)

1064 H

CRP (mg/dL)

12.1 H

Creatinine (mg/dL)
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Table 2: HLH-2004 Criteria for Hemophagocytic
Lymphohistiocytosis Observed in Case
HLH-2004 Diagnostic Criteria

Patient

Fever>38.5 °C

*Temperature 39.2 °C on admission

Splenomegaly

*Present on multiple imaging
modalities abdominal ultrasound,
CT scan of abdomen

Cytopenia with 2 of following:
hemoglobin <9 g/dL,
Platelets <100 (B/L), absolute
neutrophil count <1000

ANC 2548 on admission, platelet
count 81 (B/L)

Hypertriglyceridemia
and/or hypofibrinogenemia

Fibrinogen 257 mg/dL, Triglycerides
144 mg/dL (Within normal limits)

Hemophagocytosis in
bone marrow, spleen,
lymph node or liver

*Bone marrow biopsy with increased
number of macrophages with
hemophagocytic activity

Low or absent
Natural Killer cell activity

Flow Cytometry with NK cells making
up 6% of lymphocyte lineage

Ferritin>500 ng/mL

*6881 ng/mL

Elevated soluble CD25 (IL-2)
receptor (U/mL)

*3304 U/mL

DIFFERENTIAL DIAGNOSIS
Sepsis was at the top of the differential so the patient was
started on broad spectrum antibiotics with daptomycin,
aztreonam, and doxycycline to cover for arthropodborne infection given the high fevers and rash. A
computed tomography (CT) scan of the abdomen/pelvis
with contrast was performed and showed scarring at the
site of the previous hepatic abscess and splenomegaly.
The absence of a new hepatic abscess on imaging, along
with the patient’s upward trending fever curve over the
next 2 days while on broad spectrum antibiotics moved
the suspected diagnosis towards a non-infectious cause
of severe inflammatory disease. The patient’s ferritin level
dramatically increased from 6,800ng/mL on admission to
10,000ng/mL on day 3. The antinuclear antibody (ANA)
titer resulted as >1:640, and Anti-RNP/Sm ELISA was
>1562U/mL, concerning for an underlying autoimmune
condition. A soluble serum interleukin-2 (IL-2) receptor
level was elevated to 3,300U/mL. A bone marrow biopsy
showed an increased level of macrophages, some of
which contained phagocytized cells. Given the composite
of this primary data, along with worsening clinical status,
HLH-2004 diagnostic criteria was applied and unified this
patient’s clinical syndrome as HLH based on meeting five
of the eight criteria (Table 2).
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OUTCOME AND FOLLOW-UP
Treatment with IV dexamethasone was initiated on day 3
of admission for a suspicion of HLH. Intravenous
Immunoglobulin (IVIG) 1g/kg/day for two doses and
anakinra 100mg twice daily were also initiated on day 4 of
admission given the lab-work suggesting an underlying
rheumatologic trigger. Etoposide, a recommended
treatment for non-rheumatologic HLH, was not given
due to this patient’s extensive hepatic disease,
pancytopenia, and likely rheumatologic trigger. 6 The
patient’s fever curve, ferritin level, and transaminases
down-trended, and his rash greatly improved over the
next few days. Dexamethasone was stopped 30 days
after discharge based on improving lab-work and the
anakinra is to be continued indefinitely with rheumatology
follow-up. 60 days after initial admission, the patient’s
ferritin level normalized, and he returned to his baseline
functional independence.

DISCUSSION
HLH is a life-threatening disease marked by severe
uncontrolled inflammation. HLH in adults remains an
elusive diagnosis given its non-specific laboratory findings.
Studies have shown that marked hyper-ferritinemia
>50,000µg/L is not predictive of HLH in adult populations,
as opposed to pediatric populations in which it is 90%
sensitive and 98% specific. 7 The major obstacle to
initiating HLH treatment is a delay in diagnosis as was
evident in our case. In our patient, the soluble IL-2
receptor level, which reflects the activation of T-cells, was
highly elevated in accordance with cytokine mediated
organ dysfunction associated with HLH. 2,5 There is,
however, a time delay in obtaining the IL-2 receptor level,
which may take 3- 6 days to result. Overall, our patient’s
presentation was in line with documented cases of adult
HLH in that our patient had a fever (93% of cases),
splenomegaly (50% of cases), elevated ferritin (98% of
cases), and hemophagocytosis seen on bone marrow
biopsy (97% of cases).4,8-11 Given that diagnosis remains a
barrier to HLH treatment, future work should focus on
developing adult specific diagnostic criteria. In 2014, a
research group based in Paris constructed a diagnostic
score called the “HScore” which may be used to estimate
an individual’s risk for reactive hemophagocytic syndrome
according to weighted criteria. This tool is freely available
online, but it has limitations including non-specific cutoff
values for the criteria and it requires further validation in
prospective study.12
The principle of HLH management is to suppress the
unregulated inflammation. 2 There is a more specific
HLH-2004 treatment protocol which comes from
pediatric literature and includes an initial 8-week course of
chemo-immunotherapy with etoposide, dexamethasone,
and cyclosporine A upfront for patients who are less than

18 years of age and meet HLH-2004 diagnostic criteria.6
Early initiation of dexamethasone, which can cross the
blood brain barrier, appears to be of benefit in documented
adult cases of HLH and was in this case.2 Treatment of the
underlying trigger can often lead to control or resolution
of the secondary HLH. Our patient had an unclear but
likely rheumatologic trigger and was treated with anakinra,
an IL-1 receptor antagonist. The exact role of IL-1 in HLH
is unknown, but considering the end-product of HLH is an
increased production of cytokines, it would make sense to
see IL-1 up-regulation. 1 Anakinra has been used with
positive response in patients with HLH secondary to
Systemic Juvenile Idiopathic Arthritis, Adult Still’s disease,
Systemic Lupus Erythematosus, and even Cytomegalovirus
infection.1,3,8,9,11 It is clear that not all adult cases of HLH
require initiation of the complete HLH-2004 protocol
treatment, which includes chemotherapeutics, as these
medications carry harmful side effects.2 Use of a biological
response modifier along with dexamethasone may
achieve treatment of secondary HLH in an adult patient as
exemplified by this case. Further reporting of successful
treatment regimens is crucial to developing trigger specific
HLH treatment protocols, given that these patients carry
different prognoses based on their underlying cause.4
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